Standout Papers

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplati... 2019 2026 2021 2023 199
  1. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer (2019)
    Marcus E. Randall, Virginia L. Filiaci et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 22 from Science/Nature 60 standout
Sub-graph 1 of 21

Citing Papers

Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
PARP and PARG inhibitors in cancer treatment
2020 Standout
1 intermediate paper

Works of Thomas Rutherford being referenced

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
2015
Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer
2010

Author Peers

Author Last Decade Papers Cites
Thomas Rutherford 2273 1741 2340 2863 193 7.7k
Adnan Munkarah 1964 1736 1498 1906 180 6.1k
Hani Gabra 2167 946 2348 3199 174 7.2k
Noriomi Matsumura 1982 1172 3579 2405 209 7.6k
Noriaki Sakuragi 2498 3305 1262 2350 227 7.5k
Toshiharu Kamura 3005 2758 1494 2090 188 7.3k
Alessandro D. Santin 1937 1898 4452 3139 340 10.3k
Aikou Okamoto 1603 1058 1842 4363 258 7.8k
Hal W. Hirte 2230 572 3594 3170 154 7.9k
Masaki Mandai 2727 1652 4493 2822 333 10.3k
Shashikant Lele 1278 975 3306 2121 157 7.6k

All Works

Loading papers...

Rankless by CCL
2026